Thursday, September 01, 2022 9:48:35 AM
The Company released a video which explain the potential functions of the Epsilon tool:
"The ability to analyze and address advanced IC's reliability parameters is necessary to mitigate risk of system degradation, overheating, and possible malfunction. It can affect microchip's performance, power consumption, data storage and retrieval, heat and an early failure which may be critical in vital electronic systems. Epsilon analyzes a microchip data for reliability, power and electrothermal characteristics, and performs auto-correction in case violations found. We are now implementing an intelligent technology for Epsilon with the goal of utilizing pattern matching algorithms to formulate a smart detection of reliability issues within integrated circuits layout. The new techniques will analyze and learn weak spots within microchip's data, predicting failure models that are based on the process' physics and electrical constraints knowledge. It will take into consideration each device's function, connectivity attributes, electrical currents information, electrothermal factors and more to determine problematic spots and perform auto-correction. Particularly for FinFet and GAA FET (Gate All Around FET) technologies, a device's functionality is developed with major reliability considerations ensuring power management efficiency, optimal thermal analysis aiming for long, reliable life span. Using smart pattern matching methods, we plan to improve reliability analysis, achieving consistency and accuracy across designs within advanced manufacturing processes. As dimensions of processes shrink, IC's layout features become much more complex to analyze for electrical phenomenon. To provide an intelligent answer for these complexities, we are implementing deep learning-based pattern matching technology with the goal of ensuring efficient, 'green' microchip's power consumption, higher performance, optimized thermal distribution, and ultimately superior reliability" stated Danny Rittman, the Company's CTO.
There is no guarantee that the Company will be successful in researching, developing or implementing this system. In order to successfully implement this concept, the Company will need to raise adequate capital to support its research and, if successfully researched and fully developed, the Company would need to enter into a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product. There is no guarantee that the Company will be successful in any or all of these critical steps.
Recent GTCH News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:32:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:16:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 09:07:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:07:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 09:06:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 08:06:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 10:04:19 AM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 08/23/2023 10:01:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2023 12:00:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/17/2023 10:15:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2023 11:19:14 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 08:05:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:05:52 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 07/28/2023 08:05:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 08:05:43 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM